Amgen reveals latest updated data for BiTE drug in acute lymphoblastic leukaemia
This article was originally published in Scrip
Executive Summary
Amgen is to present the full and updated results from a Phase II study of its bispecific T cell engager (BiTE) antibody, blinatumomab (AMG 103), showing that the product achieved a high-rate of complete response (CR) in 72% of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL) and also demonstrated a median survival of nine months, with a median follow-up of 10.7 months.